LLY
Eli Lilly and Company
NYSE: LLY · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$934.60
+9.80% today
Updated 2026-04-30
Market cap
$760.43B
P/E ratio
37.03
P/S ratio
11.67x
EPS (TTM)
$22.99
Dividend yield
0.69%
52W range
$620 – $1,132
Volume
3.0M
Eli Lilly and Company (LLY) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
+5.6%
Last 4 quarters
Revenue YoY growth
+42.6%
Most recent quarter
EPS YoY growth
+41.7%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+0.0%
Last 8 reports
Positive reaction rate
63%
5 of 8 quarters
Largest single-day move
-16.2%
2025-08-07
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-04 | $7.54 | +5.2% | $1,001.79 | $1,019.14 | +1.7% |
| 2025-10-30 | $7.02 | +10.2% | $810.99 | $860.17 | +6.1% |
| 2025-08-07 | $6.31 | +12.9% | $742.45 | $622.37 | -16.2% |
| 2025-05-01 | $3.34 | -5.6% | $892.47 | $817.68 | -8.4% |
| 2025-02-06 | $5.32 | +5.0% | $834.62 | $870.43 | +4.3% |
| 2024-10-30 | $1.18 | -19.7% | $893.91 | $820.86 | -8.2% |
| 2024-08-08 | $3.92 | +50.8% | $762.82 | $880.91 | +15.5% |
| 2024-04-30 | $2.58 | +4.9% | $727.10 | $766.10 | +5.4% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $7.17 | $7.54 | +5.2% | $19.29B | +42.6% |
| 2025-09-30 | $6.37 | $7.02 | +10.2% | $17.60B | +53.9% |
| 2025-06-30 | $5.59 | $6.31 | +12.9% | $15.56B | +37.6% |
| 2025-03-31 | $3.54 | $3.34 | -5.6% | $12.73B | +45.2% |
| 2024-12-31 | $5.07 | $5.32 | +5.0% | $13.53B | +44.7% |
| 2024-09-30 | $1.47 | $1.18 | -19.7% | $11.44B | +20.4% |
| 2024-06-30 | $2.60 | $3.92 | +50.8% | $11.30B | +36.0% |
| 2024-03-31 | $2.46 | $2.58 | +4.9% | $8.77B | — |
| 2023-12-31 | $2.22 | $2.49 | +12.2% | $9.35B | — |
| 2023-09-30 | $-0.13 | $0.10 | +176.9% | $9.50B | — |
| 2023-06-30 | $1.98 | $2.11 | +6.6% | $8.31B | — |
Analyst EPS and revenue estimates for upcoming years
| Period | EPS estimate | Revenue estimate | Revenue growth | Analysts | Confidence |
|---|---|---|---|---|---|
| 2026 (E) | $36.25 | $83.5B | +28.1% | 19 | high |
| 2027 (E) | $47.50 | $107.0B | +28.1% | 19 | high |
| 2028 (E) | $60.00 | $132.0B | +23.4% | 19 | medium |
| 2029 (E) | $71.00 | $158.0B | +19.7% | 19 | medium |
| 2030 (E) | $82.00 | $184.0B | +16.5% | 19 | medium |
Frequently asked questions
Has Eli Lilly and Company beaten earnings estimates?
Eli Lilly and Company has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of +5.6% over the last 4 quarters.
How does LLY stock react to earnings?
LLY stock has moved an average of +0.0% in the trading day following earnings over its last 8 reports, with positive reactions in 63% of those quarters.
What is Eli Lilly and Company's revenue growth rate?
Eli Lilly and Company reported year-over-year revenue growth of +42.6% in its most recent quarter, with EPS growing +41.7% year-over-year.
What is the expected EPS for LLY in 2026?
Analysts expect Eli Lilly and Company to report EPS of $36.25 for fiscal year 2026, on revenue of $83.5B, based on estimates from 19 analysts.